Literature DB >> 19820419

Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors.

Hung Pham1, Monica Chen, Aihua Li, Jonathan King, Eliane Angst, David W Dawson, Jenny Park, Howard A Reber, O Joe Hines, Guido Eibl.   

Abstract

OBJECTIVES: Prostaglandin E2 (PGE2) is a product of cyclooxygenase (COX) and PGE synthase (PGES) and deactivated by 15-hydroxyprostaglandin dehydrogenase (PGDH). Down-regulation of PGDH contributes to PGE2 accumulation in lung and colon cancers but has not been identified in pancreatic cancer.
METHODS: Normal human pancreatic and tumor-matched tissues, as well as MiaPaCa-2 and BxPC-3 cell lines, were assessed for COX-2, microsomal PGES-1, PGDH, and snail homolog 1 (SNAI1) and SNAI2 expressions by real-time polymerase chain reaction and Western blotting and PGE2 by enzyme-linked immunosorbent assay.
RESULTS: Normal tissues exhibited low COX-2 messenger RNA (mRNA) and protein expressions and high PGDH mRNA and protein expressions and PGE2 levels at 13 pg/mg of protein. In contrast, tumor tissues exhibited high COX-2 mRNA and protein expressions and low PGDH mRNA and protein expressions and PGE2 levels at 32 pg/mg of protein. Tumor tissues exhibited significantly elevated expressions of SNAI2 mRNA and protein but not SNAI1 because SNAI1 and SNAI2 reportedly down-regulate PGDH expression. The COX-2-positive BxPC-3 but not the COX-2-negative MiaPaCa-2 treated with 100-nmol/L PGE2 induced phosphorylated extracellular signal-related kinase that was blocked by the mitogen-activated protein kinase kinase inhibitor U0126, demonstrating the ability of PGE2 to activate ERK.
CONCLUSIONS: These results suggest that enhanced PGE2 production proceeds through the expressions of COX-2 and microsomal PGES-1 and down-regulation of PGDH by SNAI2 in pancreatic tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19820419      PMCID: PMC2859226          DOI: 10.1097/MPA.0b013e3181baecbe

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  45 in total

1.  Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells.

Authors:  Min Tong; Yunfei Ding; Hsin-Hsiung Tai
Journal:  Carcinogenesis       Date:  2006-04-22       Impact factor: 4.944

Review 2.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

3.  Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression.

Authors:  Jason R Mann; Michael G Backlund; F Gregory Buchanan; Taki Daikoku; Vijaykumar R Holla; Daniel W Rosenberg; Sudhansu K Dey; Raymond N DuBois
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

4.  CREB-dependent cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression is mediated by protein kinase C and calcium.

Authors:  Hung Pham; Lindsay M Shafer; Lee W Slice
Journal:  J Cell Biochem       Date:  2006-08-15       Impact factor: 4.429

Review 5.  Prostaglandin E receptors.

Authors:  Yukihiko Sugimoto; Shuh Narumiya
Journal:  J Biol Chem       Date:  2007-02-28       Impact factor: 5.157

6.  A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.

Authors:  Basil F El-Rayes; Mark M Zalupski; Anthony F Shields; Ann Marie Ferris; Ulka Vaishampayan; Lance K Heilbrun; Raghu Venkatramanamoorthy; Volkan Adsay; Philip A Philip
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

7.  Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer.

Authors:  Li Yang; Joseph M Amann; Takefumi Kikuchi; Rut Porta; Marta Guix; Adriana Gonzalez; Kyung-Ho Park; Dean Billheimer; Carlos L Arteaga; Hsin-Hsiung Tai; Raymond DuBois; David P Carbone; David H Johnson
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

8.  Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer.

Authors:  Hiroyuki Matsubayashi; Jeffrey R Infante; Jordan Winter; Alison P Klein; Richard Schulick; Ralph Hruban; Kala Visvanathan; Michael Goggins
Journal:  Cancer Biol Ther       Date:  2007-07-09       Impact factor: 4.742

9.  Ang II and EGF synergistically induce COX-2 expression via CREB in intestinal epithelial cells.

Authors:  Hung Pham; Benny Chong; Romina Vincenti; Lee W Slice
Journal:  J Cell Physiol       Date:  2008-01       Impact factor: 6.384

10.  Beta-Catenin stabilizes cyclooxygenase-2 mRNA by interacting with AU-rich elements of 3'-UTR.

Authors:  Hee Kyu Lee; Sunjoo Jeong
Journal:  Nucleic Acids Res       Date:  2006-10-12       Impact factor: 16.971

View more
  13 in total

1.  Inhibition of 15-hydroxyprostaglandin dehydrogenase by Helicobacter pylori in human gastric carcinogenesis.

Authors:  Yeon-Mi Ryu; Seung-Jae Myung; Young Soo Park; Dong-Hoon Yang; Ho June Song; Jin-Yong Jeong; Sun Mi Lee; Miyeoun Song; Do Hoon Kim; Hyo-Jeong Lee; Soo-Kyung Park; Stephen P Fink; Sandy D Markowitz; Kee Wook Jung; Kyung-Jo Kim; Byong Duk Ye; Jeong-Sik Byeon; Hwoon-Yong Jung; Suk-Kyun Yang; Jin-Ho Kim
Journal:  Cancer Prev Res (Phila)       Date:  2013-02-19

2.  Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism.

Authors:  Andrea Schmidt; James Sinnett-Smith; Steven Young; Hui-Hua Chang; O Joe Hines; David W Dawson; Enrique Rozengurt; Guido Eibl
Journal:  Surgery       Date:  2017-02-20       Impact factor: 3.982

3.  Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells.

Authors:  Lubna M Mehdawi; Chandra Prakash Prasad; Roy Ehrnström; Tommy Andersson; Anita Sjölander
Journal:  Mol Oncol       Date:  2016-08-01       Impact factor: 6.603

4.  Helicobacter pylori modulates cyclooxygenase-2 and 15-hydroxy prostaglandin dehydrogenase in gastric cancer.

Authors:  Jianqiu Zhao; Shujun Wen; Xingfen Wang; Zhiguang Zhang
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

Review 5.  Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂.

Authors:  Jessica K Norberg; Earlphia Sells; Hui-Hua Chang; Srinivas R Alla; Shuxing Zhang; Emmanuelle J Meuillet
Journal:  Pharm Pat Anal       Date:  2013-03

6.  miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells.

Authors:  Hung Pham; C Ekaterina Rodriguez; Graham W Donald; Kathleen M Hertzer; Xiaoman S Jung; Hui-Hua Chang; Aune Moro; Howard A Reber; O Joe Hines; Guido Eibl
Journal:  Biochem Biophys Res Commun       Date:  2013-08-21       Impact factor: 3.575

7.  11-Oxoeicosatetraenoic acid is a cyclooxygenase-2/15-hydroxyprostaglandin dehydrogenase-derived antiproliferative eicosanoid.

Authors:  Xiaojing Liu; Suhong Zhang; Jasbir S Arora; Nathaniel W Snyder; Sumit J Shah; Ian A Blair
Journal:  Chem Res Toxicol       Date:  2011-09-30       Impact factor: 3.739

8.  Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma.

Authors:  Jee Eun Yang; Eunji Park; Hyo Jeong Lee; Hyo Jeong Kang; Kang Mo Kim; Eunsil Yu; Danbi Lee; Ju Hyun Shim; Young-Suk Lim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee
Journal:  Clin Mol Hepatol       Date:  2014-03-26

9.  Decreased PGE₂ content reduces MMP-1 activity and consequently increases collagen density in human varicose vein.

Authors:  Ingrid Gomez; Chabha Benyahia; Liliane Louedec; Guy Leséche; Marie-Paule Jacob; Dan Longrois; Xavier Norel
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

10.  Cellular uptake and antiproliferative effects of 11-oxo-eicosatetraenoic acid.

Authors:  Nathaniel W Snyder; Sonia D Revello; Xiaojing Liu; Suhong Zhang; Ian A Blair
Journal:  J Lipid Res       Date:  2013-08-14       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.